Renaissance Technologies LLC Reduces Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Renaissance Technologies LLC lessened its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 49.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 139,900 shares of the company's stock after selling 138,767 shares during the quarter. Renaissance Technologies LLC owned approximately 0.26% of Voyager Therapeutics worth $793,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at $746,000. ADAR1 Capital Management LLC grew its stake in Voyager Therapeutics by 212.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company's stock valued at $719,000 after buying an additional 86,158 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Voyager Therapeutics during the 4th quarter worth approximately $267,000. Barclays PLC boosted its position in shares of Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after acquiring an additional 37,398 shares during the period. Finally, ExodusPoint Capital Management LP grew its position in shares of Voyager Therapeutics by 99.5% during the 4th quarter. ExodusPoint Capital Management LP now owns 65,830 shares of the company's stock worth $373,000 after purchasing an additional 32,834 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at $1,478,093.33. The trade was a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on VYGR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics has an average rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Stock Performance

Shares of VYGR traded down $0.15 on Monday, reaching $3.49. The stock had a trading volume of 310,913 shares, compared to its average volume of 445,885. Voyager Therapeutics, Inc. has a 12-month low of $2.75 and a 12-month high of $9.55. The firm has a market capitalization of $193.04 million, a price-to-earnings ratio of 4.92 and a beta of 0.95. The company has a 50-day simple moving average of $3.59 and a 200-day simple moving average of $5.04.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the company posted $1.25 EPS. On average, analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.